PRIMARY STUDY

Activation of Cannabinoid Receptor 2 Prevents Colitis-Associated Colon Cancer through Myeloid Cell De-activation Upstream of IL-22 Production

Key Findings:  Resulting data revealed that THC (via activation of CB2) is a potent suppressor of aberrant immune responses by provoking coordination between APCs and T regulatory cells and as such attenuates colitis-associated colon cancer and colitis induced by anti-CD40.

Type of Study:  Animal Study

Study Result:  Positive

Study Location(s):  United States

Year of Pub:  2020


Cannabinoids Studied:  Tetrahydrocannabinol (THC)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype I

Receptors Studied:  CB2

Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines

Route of Administration:  Oral (Ingestion)



Link to study